The Tangible Benefit of 68Ga-PSMA PET/CT in Nomogram-Based Therapy Choices of High-Risk Prostate Cancer Patients With Non-Regional Lymph Node Metastases. This evidence concerns the gene FOLH1 and prostate cancer.